Gateway for Cancer Research accelerates practice-changing discoveries in cancer care by funding innovative, patient-centered Phase I and II clinical trials to improve outcomes and empower patients.
Gateway for Cancer Research centers its giving on early-phase cancer clinical trials, with a program model built to move patient-centered research through Phase I and Phase II studies. Its recent awards show support for major cancer centers and trial networks, including MD Anderson Cancer Center in Houston and Dana-Farber Cancer Institute in Boston, alongside a range of universities and hospitals engaged in cancer research. The foundation’s portfolio also points to interest in collaborative trial structures, with programs tied to ECOG-ACRIN, the National Cancer Institute, and SPORE/P20 awardees. That mix places clinical trial development at the center of its grantmaking rather than broad, general cancer philanthropy. Gateway for Cancer Research funds across cancer types and across institutions, including work in immunotherapy, targeted therapies, gene therapy, biomarkers, integrative medicine, pediatric cancers, blood cancers, and breast cancer. Its active grant programs include both unsolicited pathways and collaboration-based mechanisms, indicating a funding approach that combines direct investigator-initiated support with structured partnerships for early-stage oncology research.
In clinical trial funding, Gateway for Cancer Research gave $624,012 to The Ohio State University James Cancer Hospital for cancer research and $500,000 to University Hospitals Cleveland Medical Center for cancer research. These awards fit a pattern of backing institutions running early-stage oncology studies. The foundation also supports multi-site and collaboration-based research; recent funding includes $500,067 to The Leukemia & Lymphoma Society and $413,134 to The Regents of the University of California San Francisco, both listed for cancer research. Its stated program areas extend into Phase I and Phase II trials, translational research, correlative analysis, and patient-centric clinical research. The foundation also names integrative oncology in its program structure, through a joint program with the Society for Integrative Oncology, alongside separate pathways for decentralized clinical trial approaches and NCI-linked collaborations.
Typical awards are substantial: the 25th percentile is $197,232, the median is $275,830, and the 75th percentile is $499,834. Recent grants cluster around cancer research awards to large institutions, and several recipients appear more than once across 2023, 2024, and 2025, including MD Anderson Cancer Center, Dana-Farber Cancer Institute, and University Hospitals Cleveland Medical Center. Gateway for Cancer Research is a regular funder, not a DAF, and it does not fund individuals. It also offers at least one unsolicited pathway through its traditional and clinical trial grant programs, alongside collaboration-based programs that are invitation or partnership driven.
$5.8M
$20.3M
$9.7M
$11.2M
Most grants fall between $197K and $500K, with a median of $276K.
25th Percentile
$197K
Median
$276K
75th Percentile
$500K
About 0% of grants go to recipients in NY.
NATALIE STEWART
Sign up for a free Kindora account to access AI-generated insights into this funder's giving patterns, decision-makers, and fit signals.
Get Started FreeFree Kindora accounts unlock side-by-side comparisons with foundations that share this funder's focus areas and giving profile.
Get Started FreeSign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Grantmaking is national, with 55 grants going to U.S. recipients and none to Illinois recipients in the recent-grants list. Houston appears repeatedly through MD Anderson Cancer Center and Baylor College of Medicine, while New York recipients include The Leukemia & Lymphoma Society, University of Rochester, Memorial Sloan Kettering Cancer Center, and Columbia University Irving Medical Center. Other repeated locations include Cleveland, Boston, and Los Angeles, showing a spread across major research hubs rather than a single region.
Gateway for Cancer Research supports cancer research centered on Phase I and Phase II clinical trials, with program areas that include immunotherapy, targeted therapies, gene therapy, biomarkers and predictive assays, integrative medicine, pediatric cancers, blood cancers, and breast cancer.
Typical grants are in the mid-to-large research range: the 25th percentile is $197,232, the median is $275,830, and the 75th percentile is $499,834. Active program pages also show a traditional grant range of $200,000 to $1,500,000.
Yes, for some programs. The Gateway Traditional Grant Program accepts unsolicited applications, and the Clinical Trial Research Grants (Phase I & II) program also accepts unsolicited proposals. Other collaboration-based programs, such as the Joint ECOG-ACRIN Program, do not.
The top state by grant count is Tennessee. In the recent-grants list, however, the named recipients are spread across major research centers in many states, and none are in Illinois.
Yes. Several recipients appear in multiple years, including MD Anderson Cancer Center in 2024 and 2025, Dana-Farber Cancer Institute in 2023 and 2024, and University Hospitals Cleveland Medical Center in 2023 and 2025. That suggests repeated support for some institutions rather than one-time awards only.
2026
Source: IRS Form 990-PF, fiscal year 2026.
Current and upcoming funding from Gateway for Cancer Research that your nonprofit may be able to apply for.
Who can apply: Applications must involve eligible investigator-initiated early-phase, treatment-based cancer clinical trials conducted through or in collaboration with the ECOG-ACRIN network and aligned with Gateway's mission.
Deadline: Applications are accepted year-round and reviewed in two aggregated cycles annually; portal deadlines apply.
Who can apply: Proposals must come from principal investigators and institutions that receive NCI SPORE or P20 awards. Funding may expand a clinical trial by adding an arm, adding cohorts, generating correlative analysis, or enrolling additional patients, but cannot duplicate the SPORE award's scope of work.
Deadline: Applications are accepted year-round and aggregated for two review cycles annually; portal deadlines apply.
Who can apply: Investigator-initiated applications are welcome from academic, nonprofit, or for-profit organizations, institutions, or medical centers. The proposed study must be a novel, patient-centered Phase I or Phase II treatment-based cancer clinical trial with potential for immediate patient impact. Basic laboratory, preclinical animal, prevention, early detection, device testing, and other excluded research types are generally not eligible. The principal investigator must submit a clinical/research biosketch.
Deadline: Applications are accepted year-round; Gateway aggregates and reviews applications twice per year. LOIs must be submitted before the deadline shown in the portal.
Who can apply: Applicants must be principal investigators and institutions among the Society for Integrative Oncology membership and propose eligible integrative clinical research aligned with Gateway's mission.
Deadline: LOIs accepted year-round; Full Grant Application invitations are issued once annually for the Gateway/SIO spring peer-review meeting.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.
Most recent grants reported to the IRS.
| Recipient | Location | Amount | Year | Purpose |
|---|---|---|---|---|
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | DALLAS, TX | $750,000 | 2026 | CANCER RESEARCH |
| MD ANDERSON CANCER CENTER | HOUSTON, TX | $723,465 | 2026 | CANCER RESEARCH |
| MASSACHUSETTS GENERAL HOSPITAL | BOSTON, MA | $470,067 | 2026 | CANCER RESEARCH |
| WASHINGTON UNIVERSITY ST LOUIS | ST LOUIS, MO | $421,954 | 2026 | CANCER RESEARCH |
| BE THE MATCH FOUNDATION | MINNEAPOLIS, MN | $400,000 | 2026 | CANCER RESEARCH |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NEW YORK, NY | $378,993 | 2026 | CANCER RESEARCH |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $368,841 | 2026 | CANCER RESEARCH |
| THE JOHN HOPKINS UNIVERSITY | BALTIMORE, MD | $364,322 | 2026 | CANCER RESEARCH |
| GEORGE MASON UNIVERSITY | FAIRFAX, VA | $282,500 | 2026 | CANCER RESEARCH |
| COLUMBIA UNIVERSITY IRVING MEDICAL CENTER | NEW YORK, NY | $275,830 | 2026 | CANCER RESEARCH |
| CEDARS- SINAI MEDICAL CENTER | LOS ANGELES, CA | $262,291 | 2026 | CANCER RESEARCH |
| ICAHN SCHOOL OF MEDICINE MOUNT SINAI | NEW YORK, NY | $247,821 | 2026 | CANCER RESEARCH |
| THE OHIO STATE UNIVERSITY | COLUMBUS, OH | $199,765 | 2026 | CANCER RESEARCH |
| CHILDREN'S HOSPITAL LOS ANGELES | LOS ANGELES, CA | $188,051 | 2026 | CANCER RESEARCH |
| CITY OF HOPE COMPREHENSIVE CANCER CENTER | DUARTE, CA | $161,712 | 2026 | CANCER RESEARCH |
| DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $160,960 | 2026 | CANCER RESEARCH |
| ST JUDE CHILDREN'S HOSPITAL | MEMPHIS, TN | $134,018 | 2026 | CANCER RESEARCH |
| YALE UNIVERSITY | NEW HAVEN, CT | $21,694 | 2026 | CANCER RESEARCH |
| MD ANDERSON CANCER CENTER | HOUSTON, TX | $915,855 | 2025 | CANCER RESEARCH |
| THE OHIO STATE UNIVERSITY JAMES CANCER HOSPITAL | COLUMBUS, OH | $624,012 | 2025 | CANCER RESEARCH |
| WASHINGTON UNIVERSITY ST LOUIS | ST LOUIS, MO | $557,687 | 2025 | CANCER RESEARCH |
| THE LEUKEMIA & LYMPHOMA SOCIETY | RYE BROOK, NY | $500,067 | 2025 | CANCER RESEARCH |
| UNIVERSITY OF ROCHESTER | ROCHESTER, NY | $500,000 | 2025 | CANCER RESEARCH |
| UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER | CLEVELAND, OH | $500,000 | 2025 | CANCER RESEARCH |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | SAN FRANCISCO, CA | $413,134 | 2025 | CANCER RESEARCH |
| THE JOHN HOPKINS UNIVERSITY | BALTIMORE, MD | $364,322 | 2025 | CANCER RESEARCH |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NEW YORK, NY | $296,959 | 2025 | CANCER RESEARCH |
| MASSACHUSETTS GENERAL HOSPITAL | CHARLESTOWN, MA | $293,658 | 2025 | CANCER RESEARCH |
| COLUMBIA UNIVERSITY IRVING MEDICAL CENTER | NEW YORK, NY | $275,830 | 2025 | CANCER RESEARCH |
| ICAHN SCHOOL OF MEDICINE MOUNT SINAI | NEW YORK, NY | $247,820 | 2025 | CANCER RESEARCH |
| BE THE MATCH FOUNDATION | MINNEAPOLIS, MN | $200,000 | 2025 | CANCER RESEARCH |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | CHAPEL HILL, NC | $176,950 | 2025 | CANCER RESEARCH |
| YALE UNIVERSITY YALE CANCER CENTER | NEW HAVEN, CT | $169,755 | 2025 | CANCER RESEARCH |
| ST JUDE CHILDREN'S HOSPITAL | MEMPHIS, TN | $125,000 | 2025 | CANCER RESEARCH |
| DUKE CANCER INSTITUTE | DURHAM, NC | $93,312 | 2025 | CANCER RESEARCH |
| THE ASCO FOUNDATION | CHARLOTTE, NC | $57,500 | 2025 | CANCER RESEARCH |
| DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $50,000 | 2025 | CANCER RESEARCH |
| MD ANDERSON CANCER CENTER | HOUSTON, TX | $1,963,904 | 2024 | CANCER RESEARCH |
| DANA-FARBER CANCER INSTITUTE | BOSTON, MA | $734,881 | 2024 | CANCER RESEARCH |
| CHILDREN'S HOSPITAL LOS ANGELES | LOS ANGELES, CA | $566,667 | 2024 | CANCER RESEARCH |
| LLS PEDAL INITIATIVE LLC THE LEUKEMIA & LYMPHOMA SOCIETY INC | RYE BROOK, NY | $500,067 | 2024 | CANCER RESEARCH |
| BAYLOR COLLEGE OF MEDICINE | HOUSTON, TX | $499,667 | 2024 | CANCER RESEARCH |
| BE THE MATCH FOUNDATION | MINNEAPOLIS, MN | $266,668 | 2024 | CANCER RESEARCH |
| CITY OF HOPE COMPREHENSIVE CANCER CENTER | DUARTE, CA | $266,666 | 2024 | CANCER RESEARCH |
| MEMORIAL SLOAN-KETTERING CANCER CENTER | NEW YORK, NY | $266,513 | 2024 | CANCER RESEARCH |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CTR | DALLAS, TX | $259,394 | 2024 | CANCER RESEARCH |
| THE WISTAR INSTITUTE | PHILADELPHIA, PA | $250,000 | 2024 | CANCER RESEARCH |
| CLEVELAND CLINIC FOUNDATION | CLEVELAND, OH | $223,041 | 2024 | CANCER RESEARCH |
| UNIVERSITY OF MICHIGAN | ANN ARBOR, MI | $194,465 | 2024 | CANCER RESEARCH |
| EMORY UNIVERSITY SCHOOL OF MEDICINE | ATLANTA, GA | $169,495 | 2024 | CANCER RESEARCH |
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER
$750,000CANCER RESEARCH
MD ANDERSON CANCER CENTER
$723,465CANCER RESEARCH
MASSACHUSETTS GENERAL HOSPITAL
$470,067CANCER RESEARCH
MEMORIAL SLOAN-KETTERING CANCER CENTER
$378,993CANCER RESEARCH
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$368,841CANCER RESEARCH
GEORGE MASON UNIVERSITY
$282,500CANCER RESEARCH
THE OHIO STATE UNIVERSITY
$199,765CANCER RESEARCH
UNIVERSITY OF ROCHESTER
$500,000CANCER RESEARCH
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER
$500,000CANCER RESEARCH
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO
$413,134CANCER RESEARCH
MEMORIAL SLOAN-KETTERING CANCER CENTER
$296,959CANCER RESEARCH
UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
$176,950CANCER RESEARCH
MD ANDERSON CANCER CENTER
$1,963,904CANCER RESEARCH
CANCER RESEARCH
MEMORIAL SLOAN-KETTERING CANCER CENTER
$266,513CANCER RESEARCH
UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CTR
$259,394CANCER RESEARCH
THE WISTAR INSTITUTE
$250,000CANCER RESEARCH
UNIVERSITY OF MICHIGAN
$194,465CANCER RESEARCH
